Current views on the use of long-acting anticholinergic drug tiotropium in the treatment of bronchial asthma among children

E.V. Churyukina

Rostov State Medical University, Rostov-on-don, Russi
Kuban State Medical University, Krasnodar, Russia

ALLERGOLOGY AND IMMUNOLOGY IN PEDIATRICS, Volume 62 • Number 3 • September 2020, pp. 29 – 38
DOI: 10.24411/2500-1175-2020-00004

Despite treatment of bronchial asthma, in accordance with current recommendations, inhaled corticosteroids as monotherapy or in combination with long-acting β2 agonists, at least 40% of patients fail to achieve disease control. The long-acting anticholinergic drug Tiotropium (through a liquid inhaler Respimat) is recommended for use in adults and children over 6 years of age by experts from GINA, the Russian respiratory society and the Pediatric respiratory society as an additional strategy for achieving bronchial asthma control. The article highlights the pharmacological properties of Tiotropium and its mechanism of action in asthma. The results of the author’s own research on the use of Tiotropium in children 6–11 years of age with moderate and severe bronchial asthma in real clinical practice are presented.

  1. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Updated 2019. Available at: https://www.ginasthma.org Global Strategy for Asthma Management and Prevention. Revised 2019 // www.ginasthma.com
  2. Masoli M., Fabian D., Holt S., Beasley R. Global Initiative for Asthma (GINA) Program. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 2004; 59: 469–478.
  3. Bateman E.D., Boushey H.A., Bousquet J., Busse W.W., Clark T.J.H., Pauwels R.A., et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control study. Am J Respir. Crit Care Med 2004; 170: 836–844.
  4. Demoly P., Paggiaro P., Plaza V., Bolge S.C., Kannan H., Sohier B. et al. Prevalence of asthma control among adults in France, Germany, Italy, Spain and the UK. Eur. Respir. Rev 2009; 18: 105–112.
  5. Partridge M.R., Dal Negro R.W., Olivieri D. Understanding patients with asthma and COPD: insights from a European study. Prim Care Respir J 2011; 20: 315–323.
  6. Custovic A., Johnston S.L., Pavord I., Gaga M., Fabbri L., Bel E.H. et al. EAACI position statement on asthma exacerbations and severe asthma. Allergy 2013; 68: 1520–1531.
  7. Belgrave D.C.M., Buchan I., Bishop C., Lowe L., Simpson A., Custovic A. Trajectories of lung function during childhood. Am J Respir Crit Care Med 2014; 189: 1101–1109.
  8. Lemanske R.F. Jr, Mauger D.T., Sorkness C.A., Jackson D.J., Boehmer S.J., Martinez F.D. et al. Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. N Engl J Med 2010; 362: 975–985.
  9. Геппе Н.А., Колосова Н.Г., Архипов В.В., Мизерницкий Ю.Л., Блохин Б.М. и др. Применение тиотропия в базисной терапии бронхиальной астмы у детей. Заключение Совета экспертов Педиатрического респираторного общества // Вопросы практической педиатрии. 2017, том 12, №4, с. 77–84. DOI: 10.20953/1817-7646-2017-4-77-84.
  10. Чурюкина Э.В., Лебеденко А.А., Галкина Г.А., Дударева М.В., Левкович М.А. Клинико-иммунологические особенности фенотипа бронхиальной астмы с ожирением у детей // Аллергология и иммунология в педиатрии. 2018, №3 (54), с. 14–20.
  11. Kistemaker L.E., Gosens R. Acetylcholine beyond bronchoconstriction: roles in inflammation and remodeling. Trends in Pharmacological Sciences 2015 Mar; 36(3): 164–171.
  12. Nadel J.A., Barnes P.J. Autonomic regulation of the airways. Ann. Rev. Med. 1984, v. 35, р. 451–467.
  13. Ненашева Н.М. Бронхиальная астма. Современный взгляд на проблему / Н.М. Ненашева. — М.: ГЭОТАР-Медиа, 2018. — 304 с.: ил. — (Серия «Библиотека врача-специалиста»)
  14. Disse B., Reichl R., Speck G. et al. Ba 679 BR, a novel long-acting anticholinergic bronchodilator. Life Sci. 1993, v. 52, р. 537–544.
  15. Joos G.F. Potential usefulness of inhibiting neural mechanisms in asthma. Monaldi Arch. Chest. Dis. 2000, v. 55, р. 411–414.
  16. Mak J.C.W., Barnes P.J. // Am. Rev. Respir. Dis. 1990.V. 141.P. 1559.
  17. Fryer A.D., Jacoby D.B. // Am. J. Respir. Crit. Care Med.1998. V. 158. Suppl. 2. P. S154.
  18. Coulson F.R., Fryer A.D. Muscarinic acetylcholine receptors and airway diseases. Pharmacol. Ther. 2003, v. 98, р. 59–69.
  19. Barnes P.J. Pharmacologic Principles. In Murray and Nadel’s Textbook of Respiratory Medicine, 5th ed. 2010. p. 159–199.
  20. Чурюкина Э.В., Ващенко Т.Б., Сизякина Л.П. Оценка эффективности и безопасности ронколейкина в комплексном лечении больных гормонозависимой бронхиальной астмой тяжелого течения. Terra Medica Nova. 2004. №4 (36). С. 18.
  21. Barnes P.J. Tiotropium bromide. Expert Opin. Investig. Drugs. 2001, v. 10, р. 733–740.
  22. Disse B., Speck G.A., Rominger K.L. et al. Tiotropium (Spiriva): mechanistical considerations and clinical profile in obstructive lung disease. Life Sci. 1999, v. 64, р. 457–464.
  23. Авдеев С.Н. Роль антихолинергических препаратов при обструктивных заболеваниях легких. Consilium medicum. 2002; Том 4, №9: 478–485.
  24. Инструкция по применению лекарственного препарата для медицинского применения Спирива® Респимат®. Доступно по ссылке: http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=41ef4956-7fb7-463c-8a2b-f5d4be30896b&t= Ссылка активна на 06.02.2020.
  25. Ушкалова Е.А. Антихолинергические препараты длительного действия в лечении бронхиальной астмы. Фарматека. Пульмонология 2016; 4 (317): 34–40.
  26. Ohta S., Oda N., Yokoe T. et al. Effect of tiotropium bromide on airway inflammation and remodelling in a mouse model of asthma. Clin.Exp. Allergy. 2010, v. 40, р. 1266–1275.
  27. Buels K.S., Jacoby D.B., Fryer A.D. Non-bronchodilating mechanisms of tiotropium prevent airway hyperreactivity in a guinea-pig model of allergic asthma. Br. J. Pharmacol. 2012, v. 165, р. 1501–1514.
  28. Raemdonck K. et al. Thorax 2012; 67(1): 19–25.
  29. Bos I., Gosens R., Zuidhof A. et al. Inhibition of allergen-induced airway remodeling by tiotropium and budesonide: a comparison. Eur. Respir. J. 2007, v. 30, р. 653–661.
  30. Ненашева Н.М. Новые возможности достижения контроля астмы с помощью тиотропия бромида. Эффективная фармакотерапия. 29/2014, № 2, с. 2–10.
  31. АрхиповВ.В., АрхиповаД.Е., ЛазареваН.Б. Новые ингаляционные устройства для терапии хронической обструктивной болезни легких. Пульмонология. 2016; 26 (3): 352–356.
  32. Keating G.M. Tiotropium Respimat Soft Mist™ inhaler: a review of its use in chronic obstructive pulmonary disease. Drugs. 2014; 74 (15): 1801–1816.
  33. Churyukina E.V. Аssessment of the functional status and application of long-acting m-anticholinergic in children with bronchial asthma in real clinical practice // European Academy of Allergy and Clinical Immunology. EAACI Congress 1–5 June 2019, Lisbon, Portugal. Abstract TPO805. Wiley-Allergy. P. 456 www.eaaci.org
  34. Кожин А.А., Попова В.А., Пузикова О.З., Чурюкина Э.В., Голошубова Е.А. Особенности функционального состояния детей групп экологического риска, аспекты их иммунного статуса и возможности восстановительной терапии // Аллергология и иммунология в педиатрии. 2019. №1 (56). С. 28–36.
  35. Bryan C. Husta et al. Chest. 2017 Dec; 152(6): 1296–1305. Published online 2017 Aug 31.
  36. Qian C.J., Coulombe J., Suissa S., Ernst P. Pneumonia risk in asthma patients using inhaled corticosteroids: a quasi-cohort study. Br J Clin Pharmacol; (2017) 83; 2077–2086. doi:10.1111/bcp.13295
  37. Suissa S., Kezouh A., Ernst P. Inhaled corticosteroids and the risks of diabetes onset and progression. Am J Med 2010; 123: 1001–1006.
  38. Juniper E.F., O’Byrne P.M., Guyatt G.H. et al. Development and validation of a questionnaire to measure asthma control. Eur. Respir. J. 1999; 14: 902–907.
  39. Nathan R.A., Sorkness C.A., Kosinski M. et al. Development of the asthma control test: a survey for assessing asthma control. J. Allergy Clin. Immunol.2004; 113: 59–65.
  40. Vollmer W.M., Markson L.E., O’Connor E. et al. Association of asthma control with health care utilization and quality of life. Am. J. Respir. Crit Care Med. 1999; 160: 1647–1652.
  41. Boulet L.-P., Boulet V., Milot J. How should we quantify asthma control? Aproposal. Chest 2002; 122: 2217–2223.
  42. Белевский А.С. Тест контроля астмы — «новая игрушка» или важный инструмент? Атмосфера. Пульмонология и аллергология 2005; 1: 1–2.
  43. Огородова Л.М., Деев И.А., Селиванова П.А. GINA 2006: Контроль астмы как основная цель лечения и критерий эффективности терапии. Пульмонология 2007; 6: 42–45.
  44. Чурюкина Э.В., Никанорова М.В. Диагностический алгоритм спирометрической верификации диагноза бронхиальной астмы. Аллергология и иммунология. 2016. Т. 17. №2. С. 131–132.
  45. Lai C.K., De Guia T.S., Kim Y.Y. et al. Asthma control in the Asia-Pacific region: the Asthma Insights and Reality in Asia-Pacific Study. J. Allergy Clin. Immunol. 2003; 111: 263–268.
  46. Juniper E.F., O’Byrne P.M., Guyatt G.H. et al. Development and validation of a questionnaire to measure asthma control. Eur. Respir. J. 1999; 14: 902–907.
  47. Juniper E.F., O’Byrne P.M., Roberts J.N. Measuring asthma control in group studies: do we need airway calibre and res cue β2-agonist use? Respir. Med. 2001; 95: 319–323.
  48. Svensson K., Mork A.C., Juniper E.F. ACQ — is five out of seven items acceptable in large clinical studies? Qual. Life Res. 2003; 12: 771.
  49. Juniper E.F., Bousquet J., Abetz L. et al. Identifying «wellcontrolled» and «not wellcontrolled» asthma using the Asthma Control Questionnaire. Respir. Med. 2006; 100: 616–621.
  50. Bateman E.D., Bousquet J., Braunstein G.L. Is overall asthma control being achieved? A hypothesis-generating study. Eur. Respir. J. 2001, v. 17, p. 589–595.

Churyukina EV. Current views on the use of long-acting anticholinergic drug tiotropium in the treatment of bronchial asthma among children. Allergology and Immunology in Pediatrics. 2020;62(3):29-38. (In Russ.) https://doi.org/10.24411/2500-1175-2020-00004

For correspondense

Ella V. Churyukina, candidate of medical sciences, head of the Department of allergic and autoimmune diseases Rostov State Medical University, Rostov-on-don, associate Professor of the Department of clinical immunology, allergology and laboratory diagnostics Kuban State Medical University, Krasnodar
Address: 4/1 Bashkirskaya str., ap. 9, Rostov-on-don, 344068, Russia
E-mail: echuryukina@mail.ru

ALLERGOLOGY and IMMUNOLOGY in PEDIATRICS

Spelling error report

The following text will be sent to our editors: